Phenylephrine: Pharmacology and Clinical Use

Quick Answer

Phenylephrine is a direct-acting α-1 adrenergic receptor agonist with potent vasoconstrictor effects and no β-activity. Mechanism: Stimulates postsynaptic α-1 receptors on vascular smooth muscle → vasoconstriction → increased SVR and blood pressure. No cardiac effects: No direct inotropic or chronotropic effects; may cause reflex bradycardia via baroreceptor response to increased BP. Pharmacokinetics: Onset 1-2 minutes IV, duration 5-20 minutes, hepatic metabolism by MAO, short duration suitable for bolus or infusion. Clinical uses: Hypotension during neuraxial anesthesia (spinal/epidural), hypotension during general anesthesia, nasal decongestant (topical), mydriasis (ophthalmic), hypotension in shock (vasopressor support). Obstetric: Common for spinal-induced hypotension in cesarean section (preserves uteroplacental perfusion better than ephedrine - fetal pH higher). Dosing: IV bolus 50-100 μg, infusion 25-100 μg/min. Comparison with ephedrine: Phenylephrine pure α-agonist (vasoconstriction only), ephedrine mixed α and β (vasoconstriction + inotropy/chronotropy); phenylephrine better for spinal hypotension in obstetrics. [1-10]

Pharmacology

Chemical Structure

Structure:

• Class: Synthetic catecholamine derivative (non-catecholamine structure, not substrate for COMT)
• Relation: Analogue of epinephrine without β-hydroxyl group (removes β-activity)
• Chemical name: (-)-m-hydroxy-α-[(methylamino)methyl]benzyl alcohol
• Forms:
  • IV: For anesthesia and shock
  • Topical: Nasal decongestant (0.25-1%)
  • Ophthalmic: Mydriatic (2.5-10%)

Mechanism of Action

α-1 Adrenergic Receptor Agonism:

• Receptor: Postsynaptic α-1 receptors on vascular smooth muscle
• Signal transduction: Gq protein → phospholipase C → IP₃/DAG → ↑intracellular Ca²⁺ → smooth muscle contraction
• Effect: Potent vasoconstriction of arterioles and venules

Vascular Effects:

• Systemic vascular resistance (SVR): Increases 20-50% (dose-dependent)
• Venous return: Increased (venoconstriction increases preload)
• Blood pressure: Dose-dependent increase in MAP, systolic and diastolic
• Reflex response: Baroreceptor-mediated ↓heart rate (bradycardia)
• Regional blood flow: Reduced to kidneys, splanchnic bed, skin (vasoconstriction)

Cardiac Effects:

• Direct: None (no β-1 or β-2 activity)
• Indirect (reflex):
  • ↓Heart rate (baroreceptor reflex to hypertension)
  • No change or slight ↓in cardiac output (despite ↑afterload, ↑preload compensates partially)
  • No direct inotropic effect

Absence of β-Activity:

• No bronchodilation (no β-2)
• No cardiac stimulation (no β-1)
• No uterine relaxation (no β-2)
• No glycogenolysis (no β-2)
• No renin release (no β-1 in juxtaglomerular apparatus)

Pharmacokinetics

Administration Routes:

• IV: 100% bioavailability (primary route for anesthesia)
• IM: Variable, not used clinically
• Subcutaneous: Not recommended (risk of tissue necrosis)
• Topical: Nasal mucosa, eye
• Oral: Poor absorption, extensive first-pass, not used systemically

Intravenous Kinetics:

• Onset: 1-2 minutes
• Peak effect: 2-5 minutes
• Duration: 5-20 minutes (dose-dependent)
• Short-acting: Suitable for bolus dosing or infusion

Distribution:

• Vd: Not well characterized (rapid onset/offset)
• Protein binding: Unknown (not clinically relevant)
• Distribution: Rapid to effect site (vascular smooth muscle)

Metabolism:

• Primary enzyme: Monoamine oxidase (MAO) in liver and intestinal wall
• Not metabolized by: COMT (catechol-O-methyltransferase) - lacks catechol structure
• Metabolites: Inactive
• Hepatic metabolism: Significant first-pass if oral (why not used PO)

Elimination:

• Half-life: Short (minutes) - exact data limited
• Clearance: Rapid
• Excretion: Urine (metabolites)
• Context: Short duration makes it ideal for titration

Factors Affecting Pharmacokinetics:

• MAO inhibitors: Prolonged and exaggerated response (reduce dose 90%)
• Cocaine: Blocks neuronal uptake, potentiates response
• Tricyclic antidepressants: Block neuronal uptake (though phenylephrine is direct-acting, effect less than with indirect agents)
• Age: Similar response across ages (receptor function preserved)

Pharmacodynamics

Dose-Response:

Intravenous Bolus:

• 50 μg: Modest ↑BP (10-20 mmHg), mild ↓HR
• 100 μg: Moderate ↑BP (20-30 mmHg), moderate ↓HR
• 200 μg: Marked ↑BP (30-50 mmHg), significant ↓HR
• Duration: 5-15 minutes per bolus

Infusion:

• 25 μg/min: Mild ↑BP
• 50 μg/min: Moderate ↑BP (commonly used)
• 100 μg/min: High ↑BP
• Titrate: To maintain MAP target

Cardiovascular Effects:

• MAP: Increases dose-dependently
• Systolic BP: Increases
• Diastolic BP: Increases
• Pulse pressure: May narrow (diastolic increases proportionally more)
• Heart rate: Decreases (reflex bradycardia)
  • Can be profound (HR <50 bpm)
  • Atropine rarely needed unless symptomatic
• Cardiac output: Usually maintained or slight decrease (complex interplay: ↑afterload reduces, ↑preload and ↓HR offset)
• Stroke volume: May increase (↑preload)
• Myocardial oxygen demand: Increases (↑afterload, though ↓HR offset)

Regional Blood Flow:

• Renal: Decreased (vasoconstriction)
• Splanchnic: Decreased
• Cutaneous: Decreased (pallor)
• Coronary: Maintained or increased (↑perfusion pressure, though vasoconstriction)
• Cerebral: Maintained (autoregulation)
• Uteroplacental: Better preserved than with ephedrine (important in obstetrics)

Comparison with Ephedrine:

Clinical Use

Hypotension During Neuraxial Anesthesia

Spinal/Epidural Hypotension:

• Mechanism: Sympathetic block → vasodilation → ↓SVR and venous pooling
• Incidence: 60-80% without prophylaxis (cesarean section), 20-40% (other surgery)
• Phenylephrine advantage: Pure vasoconstriction without tachycardia

Prophylaxis vs Treatment:

• Prophylactic infusion: 25-50 μg/min starting with spinal dose, titrate to maintain MAP
• Bolus treatment: 50-100 μg when MAP drops >20% from baseline
• Combination: Many use both strategies

Comparison with Ephedrine (Obstetric Context):

• Historical: Ephedrine was "gold standard" for spinal hypotension
• Current evidence: Phenylephrine superior for fetal outcomes
  • Fetal pH: Higher with phenylephrine (less placental transfer, no fetal metabolic effects)
  • Base excess: Better with phenylephrine
  • Uteroplacental blood flow: Better preserved
  • Ephedrine problem: Crosses placenta, stimulates fetal metabolism (lactic acidosis)
• Current practice: Phenylephrine first-line for elective cesarean section
• Ephedrine reserve: If phenylephrine causes excessive bradycardia or CO inadequate

Dosing in Obstetrics:

• Infusion: 25-50 μg/min (start with spinal, titrate)
• Bolus: 50-100 μg PRN
• Target: Baseline MAP or slight reduction acceptable
• Bradycardia: If HR <50 with symptoms, give ephedrine or glycopyrrolate

Hypotension During General Anesthesia

Causes Addressed by Phenylephrine:

• Vasodilation from volatile agents, propofol
• Sympathetic block from regional anesthesia
• Hypovolemia (temporary support until fluids given)
• Sepsis (as part of multimodal support)

Use:

• Bolus: 50-100 μg for acute hypotension
• Infusion: 25-100 μg/min for persistent hypotension
• Combination: Often used with fluid boluses, treat cause

Cautions:

• Not for hypovolemic shock alone (give fluids first)
• May reduce organ perfusion (use lowest effective dose)
• Reflex bradycardia may be problematic (combine with atropine if needed)

Shock and Vasodilatory States

Septic Shock:

• Not first-line: Surviving Sepsis Campaign recommends norepinephrine
• Adjunct: May be added if norepinephrine inadequate
• Caution: Pure vasoconstriction may reduce organ perfusion

Neurogenic Shock:

• Spinal cord injury → loss of sympathetic tone
• Role: Restore vascular tone and MAP
• Often combined with fluid and other pressors

Anaphylactic Shock:

• Not adequate alone: Epinephrine (α and β) first-line
• Adjunct: May add phenylephrine for persistent hypotension

Ophthalmic Use

Mydriasis:

• Concentration: 2.5-10% eye drops
• Use: Eye examination, surgery
• Mechanism: α-1 on iris dilator muscle
• Advantage: No cycloplegia (unlike anticholinergics)
• Caution: Can precipitate angle-closure glaucoma

Nasal Decongestant

Topical:

• Concentration: 0.25-1% spray or drops
• Mechanism: Vasoconstriction of nasal mucosa
• Duration: 4-6 hours
• Rebound congestion: Rhinitis medicamentosa with prolonged use (>3 days)
• Caution: Systemic absorption can cause hypertension

Administration and Monitoring

Intravenous Preparation:

• Concentration: 100 μg/mL (1 mg in 10 mL)
• Dilution: 10 mg in 100 mL (100 μg/mL) or 10 mg in 250 mL (40 μg/mL)
• Compatibility: Most IV solutions, avoid alkaline solutions (precipitation)

Bolus Administration:

• Dose: 50-100 μg IV (may repeat q2-5min)
• Injection: Slow IV push or rapid infusion
• Monitoring: BP q1-2 min until stable

Infusion Administration:

• Rate: Start 25-50 μg/min, titrate to effect
• Titration: Every 2-5 minutes
• Maximum: Usually 200 μg/min (varies by clinical situation)
• Weaning: Gradual reduction as BP stabilizes

Monitoring:

• Blood pressure: Continuous arterial line preferred, or frequent NIBP
• Heart rate: Continuous ECG (watch for bradycardia)
• SpO₂: Ensure adequate perfusion
• Urine output: Marker of organ perfusion
• Fetal heart rate: In obstetrics (ensures uteroplacental perfusion)

Tissue Extravasation:

• Risk: Tissue necrosis (severe vasoconstriction)
• Prevention: Central line for high-dose or prolonged infusion
• Treatment if extravasation:
  • Stop infusion
  • Aspirate drug if possible
  • Inject phentolamine 5-10 mg (α-blocker) with hyaluronidase around site
  • Warm compresses
  • Plastic surgery consult if necrosis

Special Populations

Obstetrics

Cesarean Section:

• First-line vasopressor: Phenylephrine (superior fetal outcomes)
• Protocol:
  • Left uterine displacement
  • Phenylephrine infusion 25-50 μg/min starting with spinal
  • Titrate to maintain MAP near baseline
  • Ephedrine reserved for bradycardia or inadequate CO
• Fetal benefits: Higher pH, better base excess
• Maternal concerns: Nausea, bradycardia

Cardiac Disease

Aortic Stenosis:

• Caution: ↑afterload may worsen obstruction
• If needed: Use low doses, ensure adequate preload
• Alternative: Phenylephrine better than ephedrine (no tachycardia)

Ischemic Heart Disease:

• Advantage: ↓HR reduces myocardial O₂ demand
• Disadvantage: ↑afterload increases demand
• Balance: Usually acceptable if coronary perfusion maintained
• Monitor: ECG for ischemia

Elderly

Sensitivity:

• Baroreceptor function impaired (less reflex bradycardia)
• Vascular stiffness (higher BP response)
• Dosing: Start low (25 μg bolus), titrate slowly

Pediatrics

Limited data:

• Used in pediatric anesthesia
• Dosing by weight: 0.5-1 μg/kg bolus
• Similar hemodynamic effects

ANZCA Primary Exam Focus

Key Concepts

Mechanism:

• Direct α-1 adrenergic agonist
• Pure vasoconstriction (no β-activity)
• ↑SVR and blood pressure
• Reflex bradycardia (baroreceptor response)

Pharmacokinetics:

• Onset 1-2 minutes, duration 5-20 minutes
• Short-acting (bolus or infusion)
• Metabolized by MAO (not COMT)

Clinical:

• Spinal/epidural hypotension (prophylaxis and treatment)
• Obstetrics: First-line for cesarean section (better fetal outcomes than ephedrine)
• General anesthesia hypotension
• Reflex bradycardia common side effect

Comparison with Ephedrine:

• Phenylephrine: Pure α (vasoconstriction only), ↓HR, better uteroplacental perfusion, higher fetal pH
• Ephedrine: α and β (↑HR, ↑contractility), crosses placenta, causes fetal acidosis

Common Exam Questions

"Why is phenylephrine preferred over ephedrine for spinal hypotension in cesarean section?"

• Phenylephrine: Pure vasoconstriction, minimal placental transfer, better preserved uteroplacental blood flow, results in higher fetal pH and better base excess
• Ephedrine: Crosses placenta, stimulates fetal metabolism via β-receptors, causes fetal lactic acidosis, lower fetal pH
• Evidence from multiple RCTs favors phenylephrine for elective cesarean

"What are the cardiovascular effects of phenylephrine?"

• ↑SVR (vasoconstriction)
• ↑Blood pressure (systolic and diastolic)
• ↓Heart rate (reflex bradycardia via baroreceptors)
• No direct cardiac effects (no β-1 stimulation)
• Cardiac output maintained or slight decrease (complex interaction)

"Compare the mechanisms of phenylephrine and ephedrine."

• Phenylephrine: Direct-acting α-1 agonist, causes vasoconstriction only
• Ephedrine: Indirect-acting sympathomimetic (releases norepinephrine), mixed α and β effects (vasoconstriction + cardiac stimulation)

"Why does phenylephrine cause bradycardia?"

• Increases blood pressure (stimulates baroreceptors in carotid sinus and aortic arch)
• Baroreceptor reflex increases vagal tone
• Results in reflex bradycardia (opposite of direct effect)

References

1. ANZCA. Primary Examination Syllabus. Pharmacology Section.
2. Lee A et al. A quantitative, systematic review of randomized controlled trials of ephedrine versus phenylephrine. Anesth Analg. 2002;94(4):920-926.
3. Ngan Kee WD et al. Randomized, double-blinded comparison of norepinephrine and phenylephrine. Anesthesiology. 2015;122(1):61-69.
4. Smiley RM. Preventing spinal anesthesia-induced hypotension. Anesthesiology. 2008;108(5):833-834.
5. Mercier FJ. Cesarean delivery fluid management. Curr Opin Anaesthesiol. 2012;25(3):286-291.
6. Ngan Kee WD. Prevention of maternal hypotension after spinal anaesthesia for caesarean section. Curr Opin Anaesthesiol. 2010;23(3):304-309.
7. Dyer RA et al. The role of phenylephrine in the management of hypotension. Int J Obstet Anesth. 2018;35:88-95.
8. Goertz AW et al. Influence of phenylephrine on hemodynamics. Anesth Analg. 1993;76(2):432-434.